Safety and Efficacy of Pirfenidone in Advanced Idiopathic Pulmonary Fibrosis: A Nationwide Post-Marketing Surveillance Study in Korean Patients.

ABSTRACT:

Aim

The efficacy and safety of pirfenidone have been previously demonstrated in patients with mild-to-moderate idiopathic pulmonary fibrosis (IPF). However, the effect of pirfenidone in patients with advanced IPF remains unclear. Here, we investigated the effects of pirfenidone against advanced IPF in a real-world setting.

Methods

A prospective nationwide post-marketing study was conducted on 258 patients from 10 Korean institutions. Patients with a predicted forced vital capacity (FVC) less than 50% or a diffusing capacity of the lung for carbon monoxide (DLco) less than 35% at baseline were classified as the advanced IPF group.

Results

Of 219 patients included in the analysis, the majority were male (76.3%); the mean age was 67.3 years, and the advanced group accoun

SUBMITTER: Chung MP 

PROVIDER: S-EPMC7467484 | biostudies-literature | 2020 May

REPOSITORIES: biostudies-literature